Literature DB >> 16299529

Inactivating intracellular antiviral responses during adenovirus infection.

Matthew D Weitzman1, David A Ornelles.   

Abstract

DNA viruses promote cell cycle progression, stimulate unscheduled DNA synthesis, and present the cell with an extraordinary amount of exogenous DNA. These insults elicit vigorous responses mediated by cellular factors that govern cellular homeostasis. To ensure productive infection, adenovirus has developed means to inactivate these intracellular antiviral responses. Among the challenges to the host cell is the viral DNA genome, which is viewed as DNA damage and elicits a cellular response to inhibit replication. Adenovirus therefore encodes proteins that dismantle the cellular DNA damage machinery. Studying virus-host interactions has yielded insights into the molecular functioning of fundamental cellular mechanisms. In addition, it has suggested ways that viral cytotoxicity can be exploited to offer a selective means of restricted growth in tumor cells as a therapy against cancer. In this review, we discuss aspects of the intracellular response that are unique to adenovirus infection and how adenoviral proteins produced from the early region E4 act to neutralize antiviral defenses, with a particular focus on DNA damage signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299529     DOI: 10.1038/sj.onc.1209063

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  67 in total

1.  Identification of a previously unrecognized promoter that drives expression of the UXP transcription unit in the human adenovirus type 5 genome.

Authors:  Baoling Ying; Ann E Tollefson; William S M Wold
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

2.  Proteasome-dependent degradation of Daxx by the viral E1B-55K protein in human adenovirus-infected cells.

Authors:  Sabrina Schreiner; Peter Wimmer; Hüseyin Sirma; Roger D Everett; Paola Blanchette; Peter Groitl; Thomas Dobner
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

3.  Modeling adenovirus latency in human lymphocyte cell lines.

Authors:  Yange Zhang; Wen Huang; David A Ornelles; Linda R Gooding
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

4.  Serotype-specific inactivation of the cellular DNA damage response during adenovirus infection.

Authors:  Natalie A Forrester; Garry G Sedgwick; Anoushka Thomas; Andrew N Blackford; Thomas Speiseder; Thomas Dobner; Philip J Byrd; Grant S Stewart; Andrew S Turnell; Roger J A Grand
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

Review 5.  Viral and cellular interactions during adenovirus DNA replication.

Authors:  Matthew Charman; Christin Herrmann; Matthew D Weitzman
Journal:  FEBS Lett       Date:  2019-12-17       Impact factor: 4.124

6.  Intranuclear targeting and nuclear export of the adenovirus E1B-55K protein are regulated by SUMO1 conjugation.

Authors:  Kathrin Kindsmüller; Peter Groitl; Barbara Härtl; Paola Blanchette; Joachim Hauber; Thomas Dobner
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-11       Impact factor: 11.205

7.  The adenovirus E4 ORF3 protein binds and reorganizes the TRIM family member transcriptional intermediary factor 1 alpha.

Authors:  Mark A Yondola; Patrick Hearing
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

Review 8.  Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation.

Authors:  Andrew N Blackford; Roger J A Grand
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

9.  E1B 55k-independent dissociation of the DNA ligase IV/XRCC4 complex by E4 34k during adenovirus infection.

Authors:  Sumithra Jayaram; Timra Gilson; Elana S Ehrlich; Xiao-Fang Yu; Gary Ketner; Les Hanakahi
Journal:  Virology       Date:  2008-10-25       Impact factor: 3.616

10.  Differential requirements of the C terminus of Nbs1 in suppressing adenovirus DNA replication and promoting concatemer formation.

Authors:  Seema S Lakdawala; Rachel A Schwartz; Kevin Ferenchak; Christian T Carson; Brian P McSharry; Gavin W Wilkinson; Matthew D Weitzman
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.